Allarity Therapeutics has opened enrollment for a new Phase 2 study that combines its dual PARP/tankyrase inhibitor stenoparib with temozolomide in patients with relapsed small‑cell lung cancer (SCLC). The trial, registered as NCT06681220, is conducted in partnership with the U.S. Department of Veterans Affairs (VA) and is fully funded through the VA’s Special Emphasis Panel on Precision Oncology.
The study will recruit patients at 11 VA sites nationwide and will use a blood‑based biomarker developed by the VA Lung Precision Oncology Program to identify individuals most likely to benefit from the combination. By leveraging the VA’s funding and infrastructure, Allarity can accelerate patient recruitment and data collection while demonstrating the safety and efficacy of stenoparib in a high‑need indication.
Stenoparib’s dual mechanism—PARP inhibition combined with tankyrase inhibition that blocks WNT signaling—has already earned FDA Fast Track designation for advanced ovarian cancer in August 2025. Expanding the drug into SCLC broadens its therapeutic portfolio and taps into a market where WNT pathway dysregulation is common and treatment options are limited.
The VA partnership is a significant endorsement. Full funding removes a major cash‑burn hurdle for Allarity, a micro‑cap company that has historically relied on external financing. The partnership also provides access to a large, well‑characterized veteran population and a biomarker platform that can streamline patient selection and potentially improve trial efficiency.
CEO Thomas Jensen emphasized the strategic importance of the trial: “Opening enrollment marks an important step in exploring stenoparib’s potential as a combination agent in a disease with unmet needs. The VA’s full support underscores confidence in our science and accelerates our path to regulatory approval.”
Allarity’s financial position remains tight; the company’s cash reserves are modest and its burn rate is high. The VA’s full funding therefore represents a critical lifeline that could extend the company’s runway and reduce the need for additional capital raises. Analysts have previously set a target price of $9.50, reflecting optimism that successful clinical outcomes could unlock significant upside.
The trial’s biomarker‑driven design aligns with Allarity’s broader strategy of using companion diagnostics to identify responsive patient subgroups. If the combination shows favorable safety and preliminary efficacy, it could position stenoparib as a versatile therapy for cancers driven by WNT signaling, opening opportunities beyond ovarian cancer and SCLC.
The partnership also signals confidence from a major public‑sector payer, which could facilitate future reimbursement discussions and broaden the drug’s market reach if regulatory approval is achieved.
Allarity’s next milestones will include interim safety and efficacy readouts, which are expected in the first half of 2027. Positive results could accelerate regulatory submissions and expand the drug’s indication portfolio, potentially transforming the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.